Becton, Dickinson and Company $BDX Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 29,913 shares of the medical instruments supplier’s stock after acquiring an additional 2,915 shares during the quarter. State of Alaska Department of Revenue’s holdings in Becton, Dickinson and Company were worth $5,354,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Auto Owners Insurance Co increased its stake in Becton, Dickinson and Company by 22,225.2% in the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. State Street Corp boosted its stake in shares of Becton, Dickinson and Company by 8.5% during the second quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares during the period. First Eagle Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Finally, Bank of America Corp DE bought a new position in shares of Becton, Dickinson and Company in the second quarter worth about $474,993,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on BDX shares. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Bank of America raised their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. UBS Group started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. TD Cowen lifted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Barclays assumed coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an “underweight” rating and a $165.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $185.07.

Becton, Dickinson and Company Stock Down 1.3%

Shares of BDX stock traded down $2.42 on Friday, hitting $191.34. The stock had a trading volume of 1,412,670 shares, compared to its average volume of 1,816,545. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $195.99. The business has a 50 day moving average price of $184.03 and a 200 day moving average price of $163.70. The company has a market cap of $52.72 billion, a PE ratio of 57.63, a P/E/G ratio of 13.06 and a beta of 0.21. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 6,906 shares of company stock valued at $1,265,855. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.